NCT06718140
tFUS for Memory in mNCD and Healthy Adults
Enrolling by Invitation
PHASE1Ages 50–85InterventionalBasic scienceMedical University of South CarolinaInvestigator-initiated
~25 participants
Updated 2025-11-24 on ClinicalTrials.gov
What's tested:Transcranial Focused Ultrasound
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Face Name Associative Memory Task (Episodic Memory) effects
Measured over Pre- to post-stimulation (within approximately a 1 hour time period)
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesSouth Carolina1
Study leadership
- Kevin Caulfield, PhD · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age 50-85
English as a first/primary language
Capacity to consent
No Diagnosis of mNCD or dementia
Age 50-85
English as a first/primary language
Diagnosed with mNCD by a healthcare provider within the past 2 years per NIA-AA or DSM-5 criteria
Has ≥ 2 impaired scores within one cognitive domain OR ≥ 1 impaired score in ≥ 3 domains, where impaired score is defined as ≤ 16th percentile using demographically-corrected norms
Must have a co-participant (e.g., spouse, adult child, relative, sibling, cohabitor, friend, or caregiver) with at least weekly in-person contact with the participant
Exclusion
Current substance use disorder, bipolar disorder, or schizophrenia spectrum or other psychotic diagnosis
Daily/weekly anticholinergic or sedative use. Stimulants may be used pending investigator review. Cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants are allowed if on a stable regimen for 4 weeks prior to enrollment
History of significant or unstable conditions that may impact cognition, such as significant cardiac, cerebrovascular, or metabolic disease, developmental disorder, or other neurologic disease (e.g., moderate to severe TBI, seizures)
MRI or tFUS contraindications (e.g., metal implants, claustrophobia, conditions or treatments that lower seizure threshold, taking medications that have short half-lives)
Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days
Prior diagnosis of dementia or major neurocognitive disorder per NIA-AA or DSM-5 criteria, and telephone interview for cognitive status (TICS) score ≤ 22
Current substance use disorder, bipolar disorder, or schizophrenia spectrum or other psychotic diagnosis
Daily/weekly anticholinergic or sedative use. Stimulants may be used pending investigator review. Cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants are allowed if on a stable regimen for 4 weeks prior to enrollment
History of significant or unstable conditions that may impact cognition, such as significant cardiac, cerebrovascular, or metabolic disease, developmental disorder, or other neurologic disease (e.g., moderate to severe TBI, seizures)
MRI or tFUS contraindications (e.g., metal implants, claustrophobia, conditions or treatments than lower seizure threshold, taking medications that have short half-lives)
Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days
What this trial measures
- Face Name Associative Memory Task (Episodic Memory) effectsPre- to post-stimulation (within approximately a 1 hour time period)
Determine the within-subject effects of tFUS on episodic memory (Face Name Associative Memory Task)
- Electroencephalography (EEG) effectsPre- to post-stimulation (within approximately a 1 hour time period)
Determine the effects of tFUS on EEG recorded from scalp electrodes from pre- to post-stimulation. The investigators will evaluate broadband effects ranging from delta (1-4Hz) to beta (25-40Hz) ranges.